An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Radicava

Chemical Nameedaravone
Dosage FormInjection (intravenous; 30 mg/100 mL)
Drug ClassMiscellaneous
SystemNervous
CompanyMitsubishi Tanabe
Approval Year2017

Indication

  • To treat patients with amyotrophic lateral sclerosis (ALS).
Last updated on 10/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Radicava (edaravone) Prescribing Information2018Mitsubishi Tanabe Pharma America, Inc., a US subsidiary of Mitsubishi Tanabe Pharma Corporation, Jersey City, NJ
Document TitleYearSource
Clinical review report: Edaravone (Radicava).2019CADTH
Document TitleYearSource
Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis.2019Neurological Sciences